These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16882055)

  • 1. Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer.
    Kato T; Suzuki H; Komiya A; Imamoto T; Naya Y; Tobe T; Ichikawa T
    Int J Urol; 2006 Jul; 13(7):915-9. PubMed ID: 16882055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
    BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of sterile pyuria in association to elevated PSA values in the diagnosis of non-palpable prostate cancer?
    Demir S
    Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study.
    Seo HK; Chung MK; Ryu SB; Lee KH;
    Urology; 2007 Dec; 70(6):1109-12. PubMed ID: 18158028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
    Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
    Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings.
    Inahara M; Suzuki H; Kojima S; Komiya A; Fukasawa S; Imamoto T; Naya Y; Ichikawa T
    Urology; 2006 Oct; 68(4):815-9. PubMed ID: 17070359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
    Okegawa T; Kinjo M; Nutahara K; Higashihara E
    Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients.
    Guichard G; Larré S; Gallina A; Lazar A; Faucon H; Chemama S; Allory Y; Patard JJ; Vordos D; Hoznek A; Yiou R; Salomon L; Abbou CC; de la Taille A
    Eur Urol; 2007 Aug; 52(2):430-5. PubMed ID: 17412489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
    BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-prostatic massage examination for prediction of asymptomatic prostatitis in needle biopsies: a prospective study.
    Tekin A; Yuksel A; Tekin S; Gumrukcu G; Aslan AR; Sengor F
    J Urol; 2009 Aug; 182(2):564-8; discussion 568-9. PubMed ID: 19524953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The assessment of pathological PSA values by the general practitioner--observation or intervention?].
    Braun KP; Brookman-Amissah S; May M; Grassmel Y; Hoschke B; Braun V
    Aktuelle Urol; 2009 May; 40(3):171-4. PubMed ID: 19479670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
    Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
    Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer?
    Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H
    Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.